Clementia Pharmaceuticals, Inc.
(NASDAQ : CMTA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.09%34.480.9%$1196.77m
JNJJohnson & Johnson 1.58%143.200.7%$1130.33m
BMYBristol-Myers Squibb Co. 2.05%60.351.0%$997.01m
MRKMerck & Co., Inc. 0.66%79.300.7%$854.78m
ABBVAbbVie, Inc. 0.75%99.621.9%$817.19m
LLYEli Lilly & Co. 2.06%167.241.1%$713.46m
AZNAstraZeneca Plc 1.20%54.451.2%$304.74m
RPRXRoyalty Pharma Plc 0.20%45.820.1%$253.17m
VXRTVaxart, Inc. -13.16%6.400.0%$194.99m
NVSNovartis AG 1.05%88.490.2%$162.08m
GSKGlaxoSmithKline Plc -0.22%41.130.2%$122.26m
RGENRepligen Corp. 0.92%127.817.2%$121.24m
NVONovo Nordisk A/S -0.36%66.120.1%$94.49m
RETAReata Pharmaceuticals, Inc. 2.37%161.593.4%$89.79m
SNYSanofi 0.91%52.090.2%$80.85m

Company Profile

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.